Lead Product(s): Dichlorphenamide
Therapeutic Area: Rare Diseases and Disorders Product Name: Keveyis
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Xeris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 24, 2021
The acquisition diversifies revenue base with two rapidly growing brands in Xeris’ Gvoke® and Strongbridge’s KEVEYIS®.